# COMPREHENSIVE MANUAL MAPPING
## Investigator Brochure (Pralsetinib/RO7499790) to Drug Safety Report Template

**Document Purpose:** This mapping table identifies which sections of the Investigator Brochure (IB) Version 10 can be used to populate specific fields in the Drug Safety Report (DSR) template.

**Drug Information:**
- INN: Pralsetinib
- Trade Name: GAVRETO
- RO Number: RO7499790
- IB Version: 10 (April 2025)

---

## SECTION 1: HEADER & METADATA FIELDS

### Cover Page Information Table

| Template Field | IB Source Section | IB Page(s) | Notes |
|---|---|---|---|
| **[INSERT_DRUG_NAME]** | Section 1.1, Title Page | 1, 15 | "Pralsetinib" or "RO7499790" |
| **[INSERT_TRADE_NAME]** | Title Page | 1 | "GAVRETO" |
| **[INSERT_RO_NUMBER]** | Title Page | 1 | "RO7499790" |
| **[INSERT_COMPANY_NAME]** | Title Page | 1 | "F. Hoffmann-La Roche Ltd" |

---

## SECTION 2: EXECUTIVE SUMMARY FIELDS

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **[INSERT_EXECUTIVE_SUMMARY]** | Section 1 (Summary) | 15-22 | Comprehensive overview combining:<br>- Section 1.1: Scientific Rationale<br>- Section 1.4.2: Efficacy summary<br>- Section 1.4.3: Safety summary |
| **[INSERT_SIGNAL_DESCRIPTION]** | Section 6.3-6.4 | 100-107 | Use specific identified risk from:<br>- Table 28: Summary of Important Identified Risks<br>- Section 6.4: Identified Risks and Adverse Drug Reactions |
| **[INSERT_BACKGROUND_CONTEXT]** | Section 2.1-2.2 | 23 | - Section 2.1: Background on RET Kinase<br>- Section 2.2: Current Therapies and Unmet Medical Need |
| **[INSERT_KEY_FINDINGS]** | Section 1.4.3, Section 5.5 | 22, 87-99 | Summary from clinical safety sections |

---

## SECTION 3: INTRODUCTION SECTION (Section 1 of DSR)

### 1.1 Objectives of Report

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **[INSERT_INTRODUCTION_TEXT]** | Section 2.3 | 24 | Scientific Rationale for pralsetinib development |
| **[INSERT_OBJECTIVE_1]** | N/A | N/A | **Cannot be populated from IB** - Objectives are report-specific and must be defined based on the specific safety signal being evaluated |
| **[INSERT_OBJECTIVE_2]** | N/A | N/A | **Cannot be populated from IB** |
| **[INSERT_OBJECTIVE_3]** | N/A | N/A | **Cannot be populated from IB** |

### 1.2.1 Drug Background

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **[INSERT_DRUG_BACKGROUND]** | Multiple sections | Various | Combine information from:<br>- Section 1.1: Scientific Rationale (p. 15)<br>- Section 2.1: Background on RET Kinase (p. 23)<br>- Section 2.3: Scientific Rationale (p. 24)<br>- Section 3.1: Physical and Chemical Properties (p. 25)<br>- Section 3.2: Clinical Formulation (p. 25) |

#### 1.2.1.1 Therapeutic Indications

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **[INSERT_THERAPEUTIC_INDICATIONS]** | Section 6.1 | 99 | Copy verbatim from "Approved Indications":<br>- RET fusion-positive NSCLC<br>- RET-mutant MTC (≥12 years)<br>- RET fusion-positive thyroid cancer (≥12 years) |

#### 1.2.1.2 Relevant Information in the core RMP

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **[INSERT_RMP_INFORMATION]** | Section 6.4 | 101-107 | Use Table 28: Summary of Important Identified Risks<br>Key risks include:<br>- Interstitial lung disease/Pneumonitis<br>- Hepatotoxicity<br>- Hemorrhagic events<br>- Hypertension<br>- Tumor lysis syndrome<br>- Severe infections (NEW in Version 10)<br>- Wound healing complications<br>- Embryo-fetal toxicity |

#### 1.2.1.3 Patient Exposure

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **[INSERT_PATIENT_EXPOSURE]** | Multiple sections | Various | Combine data from:<br>- Section 5.4.1: Study BO42863 patient numbers (p. 82-85)<br>- Section 5.4.2: Study ML42439 patient numbers (p. 86)<br>- Section 5.6: Marketing Experience (p. 99)<br>"Estimated cumulative total of 2,322 patients have received GAVRETO from marketing experience as of IBD (4 September 2020)" |

### 1.2.2 Background on [SAFETY_TOPIC]

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **[INSERT_SAFETY_TOPIC_BACKGROUND]** | Section 6.4 | 101-107 | Use description from Table 28 for the specific safety topic.<br>**Example for Severe Infections:**<br>From Section 6.3-6.4 and updates in Version 10 |

#### 1.2.2.1 Epidemiological Background

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **[INSERT_EPIDEMIOLOGICAL_BACKGROUND]** | Limited in IB | N/A | **Mostly cannot be populated from IB**<br>- IB provides limited epidemiological data<br>- May need external literature for population-level epidemiology<br>- Can reference cancer-specific infection risks from Section 2.2 (Current Therapies) if relevant |

#### 1.2.2.2 Factors Responsible for Increased Susceptibility

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **[INSERT_SUSCEPTIBILITY_FACTORS]** | Sections 6.4, 6.6 | 101-113 | Combine:<br>- Risk factors from Table 28<br>- Section 6.6: Special Patient Populations<br>- Relevant medical history considerations from clinical trial descriptions |

#### 1.2.2.3 Common Types and Management

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **[INSERT_COMMON_TYPES_MANAGEMENT]** | Section 6.3-6.4 | 100-107 | Use management guidance from:<br>- Section 6.3: Warnings and Precautions<br>- Clinical management described in identified risks<br>**Note:** Management details may be limited; clinical trial protocols may provide additional info |

#### 1.2.2.4 Treatment Recommendations

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **[INSERT_TREATMENT_RECOMMENDATIONS]** | Section 6.3 | 100 | Extract from dose modification guidance in Warnings and Precautions<br>**Note:** Full dose modification tables typically in protocol documents or prescribing information, not fully detailed in IB |

---

## SECTION 4: METHODOLOGY SECTION (Section 2 of DSR)

### 2.1 Relevant Toxicology Information

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **[INSERT_METHODOLOGY_OVERVIEW]** | Section 4 | 26-45 | High-level overview of nonclinical studies program |
| **[INSERT_TOXICOLOGY_INFORMATION]** | Section 4.3 | 34-45 | Comprehensive toxicology data:<br>- Section 4.3.1: Introduction to tox program<br>- Section 4.3.3: Repeat-Dose Toxicity<br>- Section 4.3.3.1: **Effects on Hematologic and Lymphoid Systems** (p. 36)<br>- Table 4: Overview of Repeat-Dose Toxicity Studies<br>- Table 5: Summary of Mortality and Exposures<br>- Table 6: Pharmacologic Effects and Toxicokinetics |

### 2.2 Analysis of Company Sponsored Clinical Trials

#### Study Design Information

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **[INSERT_CLINICAL_TRIAL_ANALYSIS_OVERVIEW]** | Section 2.4, Section 5.1 | 24, 46 | Overview of Clinical Development program |
| **[INSERT_STUDY_1]** | Section 5.4.1 | 82-85 | **Study BO42863: ARROW Study**<br>- Primary pivotal study for all indications |
| **[INSERT_STUDY_DESIGN]** | Section 5.4.1 | 82 | Phase I/II, open-label, multicenter study |
| **[INSERT_STUDY_POPULATION]** | Section 5.4.1 | 82-85 | - RET fusion-positive NSCLC<br>- RET-altered thyroid cancer<br>- Other RET fusion-positive tumors |
| **[INSERT_TREATMENT_ARMS]** | Section 5.5.1.1 | 87 | Table 22: Phase I Dose Escalation Summary<br>- Dose range: 30 mg to 600 mg QD<br>- MTD: 400 mg QD<br>- Phase II recommended dose: 400 mg QD |
| **[INSERT_PRIMARY_ENDPOINT]** | Section 5.4.1 | 82 | - ORR (Overall Response Rate)<br>- DOR (Duration of Response) |
| **[INSERT_STUDY_1_DETAILS]** | Sections 5.4.1, 5.5.1 | 82-95 | Detailed efficacy and safety results |

#### Second Study Information

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **[INSERT_STUDY_2]** | Section 5.4.2 | 86 | **Study ML42439: MyTACTIC Study (Arm O)** |
| **[INSERT_STUDY_DESIGN]** | Section 5.4.2 | 86 | Open-label, multi-cohort basket study |
| **[INSERT_STUDY_POPULATION]** | Section 5.4.2 | 86 | Patients with RET fusion-positive solid tumors |
| **[INSERT_TREATMENT_ARMS]** | Section 5.4.2 | 86 | Arm O: Pralsetinib monotherapy |
| **[INSERT_PRIMARY_ENDPOINT]** | Section 5.4.2 | 86 | Table 21: cORR (confirmed objective response rate) |
| **[INSERT_STUDY_2_DETAILS]** | Sections 5.4.2, 5.5.4 | 86, 96-99 | Detailed efficacy and safety results |

### 2.3 Analysis of Company Safety Database

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **[INSERT_SAFETY_DATABASE_ANALYSIS]** | Section 5.6 | 99 | Marketing Experience section:<br>"Since the IBD (4 September 2020), an estimated cumulative total of 2,322 patients have received GAVRETO from marketing experience" |
| **[INSERT_CASE_ANALYSIS_STRATEGY]** | Limited in IB | N/A | **Cannot be fully populated from IB**<br>- IB does not contain detailed case analysis strategies<br>- Must be defined specifically for the DSR based on safety database query parameters |

---

## SECTION 5: RESULTS SECTION (Section 3 of DSR)

### 3.1 Relevant Toxicology Results

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **[INSERT_RESULTS_OVERVIEW]** | Section 4.4 | 42-45 | Nonclinical Integrated Analysis |
| **[INSERT_TOXICOLOGY_RESULTS]** | Section 4.3 | 34-45 | Comprehensive toxicology findings from all studies |

#### 3.1.1 Hematologic and Lymphoid Systems

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **[INSERT_HEMATOLOGIC_RESULTS]** | Section 4.3.3.1 | 36 | **CRITICAL SECTION:**<br>"Effects on Hematologic and Lymphoid Systems"<br>- Detailed findings from repeat-dose toxicity studies<br>- Species-specific effects in rats and monkeys<br>- Dose-dependent changes<br>- Reversibility data (if available) |

### 3.2 Evidence from Company Sponsored Clinical Trials

#### 3.2.1 Study Results

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **[INSERT_CLINICAL_TRIAL_EVIDENCE]** | Sections 5.4-5.5 | 82-99 | Overall summary of clinical findings |
| **[INSERT_STUDY_1_RESULTS_OVERVIEW]** | Section 5.4.1 | 82-85 | **Study BO42863: ARROW Study**<br>- Table 19: Summary of Efficacy Data for NSCLC Patients<br>- Table 20: Summary of Efficacy Data for Thyroid Cancer Patients |

##### Fatal Events (Grade 5)

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **[INSERT_FATAL_EVENTS_NARRATIVE]** | Section 5.5.1.2.4 | 91 | **Deaths** subsection<br>- Description of fatal AEs<br>- Relationship to study drug<br>**Note:** Individual patient narratives NOT in IB; found in CSRs |
| **[INSERT_N] fatal events** | Section 5.5.1.2.4 | 91 | Specific count of fatal events by safety topic |
| **[INSERT_MIN] to [INSERT_MAX] days** | Limited in IB | 91 | Time to onset data may be limited in IB summary |
| **[INSERT_MEDIAN] days** | Limited in IB | 91 | Median time to onset may be in detailed safety tables |

**IMPORTANT NOTE:** Individual case narratives with complete demographic, medical history, clinical course details are **NOT** included in the Investigator Brochure. These must come from:
- Clinical Study Reports (CSRs)
- Safety Database case reports
- Individual case listings

##### Grade 3-4 Events

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **[INSERT_GRADE34_NARRATIVE]** | Section 5.5.1.2.3 | 90-91 | **Adverse Events by Intensity**<br>- Table 25: Grade ≥3 AEs occurring in ≥10% of patients<br>- Specific counts by preferred term |
| **Distribution by MedDRA PT** | Table 25 | 91 | Direct extraction of Grade 3-4 events by PT |

##### Opportunistic Events

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **[INSERT_OPPORTUNISTIC_NARRATIVE]** | Section 6.4 | 101-107 | **For Severe Infections:**<br>Section 6.3 (Warnings) and 6.4 updates in Version 10 specifically added severe infections details |

##### Related Adverse Events Analysis

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **[INSERT_RELATED_AE_ANALYSIS]** | Section 5.5.1.2.2 | 89-90 | **Adverse Events by Relatedness**<br>- Table 24: Treatment-Related AEs occurring in ≥20% of patients |

#### 3.2.2 Second Study Results

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **[INSERT_STUDY_2_RESULTS]** | Sections 5.4.2, 5.5.4 | 86, 96-99 | **Study ML42439: MyTACTIC (Arm O)**<br>- Table 21: Efficacy Summary<br>- Table 27: Overall Safety Summary<br>- Section 5.5.4: Detailed safety breakdown |

### 3.3 Evidence from Company Safety Database

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **[INSERT_SAFETY_DATABASE_EVIDENCE]** | Section 5.6 | 99 | Marketing Experience data |
| **[INSERT_CUTOFF_DATE]** | Section 5.6 | 99 | IBD date: 4 September 2020<br>Data current through IB version date (April 2025) |
| **[INSERT_N] cases** | Section 5.6 | 99 | "2,322 patients have received GAVRETO from marketing experience" |
| **[INSERT_SOC]** | Depends on safety topic | Various | Must match MedDRA SOC for the safety topic being analyzed |
| **[INSERT_VERSION]** | Not specified in IB | N/A | MedDRA version used in clinical trials - check CSRs |

#### 3.3.1 Serious Cases - All Grades

**CRITICAL NOTE:** The IB provides **aggregate summary data only**. Detailed case-level information including:
- Individual patient demographics
- Detailed medical histories
- Complete clinical courses
- Individual laboratory findings
- Individual causality assessments
- Case narratives

...are **NOT available in the Investigator Brochure**. This information must be obtained from:
- Safety Database case reports
- Clinical Study Reports (CSRs)
- Line listings and case report forms

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **[INSERT_SERIOUS_CASES_OVERVIEW]** | Section 5.5.1.2.5 | 91-92 | **Serious Adverse Events**<br>- Table 26: SAEs occurring in ≥2% of patients |
| **[INSERT_GRADE5_CASES_NARRATIVE]** | Section 5.5.1.2.4 | 91 | Deaths section - aggregate data only |
| **[INSERT_GRADE4_CASES_NARRATIVE]** | Table 25, Section 6.4 | 91, 101-107 | Life-threatening events from Grade ≥3 table and identified risks |
| **[INSERT_GRADE3_CASES_NARRATIVE]** | Table 25 | 91 | Grade 3 events from AE intensity table |
| **[INSERT_UNKNOWN_GRADE_NARRATIVE]** | Limited in IB | N/A | May be mentioned in marketing experience section |
| **[INSERT_GRADE12_NARRATIVE]** | Section 5.5.1.2.1 | 89 | **Overview of Adverse Events**<br>- Table 23: AEs occurring in ≥20% of patients (any grade) |

#### 3.3.2 Non-serious Cases

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **[INSERT_NONSERIOUS_CASES_NARRATIVE]** | Section 5.5.1.2.1 | 89 | Derive from Table 23 (all AEs) minus SAEs from Table 26 |

#### 3.3.3 Summary of Safety Results

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **[INSERT_SAFETY_SUMMARY]** | Multiple sections | Various | Synthesize from:<br>- Section 1.4.3: Safety Summary (p. 22)<br>- Section 5.5: Clinical Safety (p. 87-99)<br>- Section 6.4: Identified Risks (p. 101-107) |
| **[INSERT_KEY_FINDING_1-4]** | Sections 1.4.3, 5.5 | 22, 87-99 | Extract 3-5 key safety findings most relevant to the safety topic |

---

## SECTION 6: DISCUSSION SECTION (Section 4 of DSR)

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **[INSERT_DISCUSSION_OVERVIEW]** | Limited in IB | N/A | **Mostly cannot be populated from IB**<br>- IB presents data but does not provide interpretive discussion suitable for DSR |
| **[INSERT_CLINICAL_SIGNIFICANCE]** | Section 6.3-6.4 | 100-107 | Can extract clinical significance from:<br>- Warnings and Precautions descriptions<br>- Risk characterization in Table 28 |
| **[INSERT_MECHANISTIC_CONSIDERATIONS]** | Sections 1.1, 2.1, 4.1 | 15, 23, 26-29 | Mechanism of action information:<br>- Section 1.1: Scientific Rationale<br>- Section 2.1: Background on RET Kinase<br>- Section 4.1: Nonclinical Pharmacology |
| **[INSERT_COMPARISONS]** | Limited in IB | N/A | **Cannot be well populated from IB**<br>- IB contains limited comparative data vs. other RET inhibitors or standard of care |
| **[INSERT_LIMITATIONS]** | N/A | N/A | **Cannot be populated from IB**<br>- Limitations must be defined in context of the DSR analysis |
| **[INSERT_RISK_MANAGEMENT]** | Section 6.3 | 100-107 | Extract risk management recommendations from Warnings and Precautions |

---

## SECTION 7: CONCLUSIONS SECTION (Section 5 of DSR)

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **[INSERT_CONCLUSIONS_OVERVIEW]** | Section 1.4.3 | 22 | High-level safety conclusions from Summary |
| **[INSERT_DATA_SOURCE_1-3]** | Sections 5.1, 5.4, 5.6 | 46, 82-99 | List data sources:<br>- Nonclinical studies<br>- Clinical trials (ARROW, MyTACTIC)<br>- Marketing experience |
| **[INSERT_CONCLUSION_1-4]** | Multiple sections | Various | Synthesize from:<br>- Section 1.4.3: Safety summary<br>- Section 6.4: Risk characterization<br>- Specific findings from Results section |
| **[INSERT_FINAL_ASSESSMENT]** | Section 6.4 | 101-107 | Overall benefit-risk assessment language from identified risks section |

---

## SECTION 8: REFERENCES SECTION (Section 6 of DSR)

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **[INSERT_REFERENCE_1-10]** | Section 7 | 115-119 | **References**<br>- Section 7.1: Sponsor Reports<br>- Section 7.2: Literature References<br>**Note:** The IB itself should be cited as a reference in the DSR |

**Recommended IB Citation Format:**
```
F. Hoffmann-La Roche Ltd. Investigator's Brochure: RO7499790 (pralsetinib/GAVRETO). 
Version 10. April 2025.
```

---

## SECTION 9: APPENDICES (Section 7 of DSR)

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **[INSERT_APPENDIX_TITLE_1-9]** | Appendices 1-4 | 120-150 | IB contains:<br>- Appendix 1: Summary of Nonclinical Pharmacology Studies<br>- Appendix 2: Summary of Nonclinical PK and Metabolism Studies<br>- Appendix 3: Summary of Toxicology Studies<br>- Appendix 4: Summary of Clinical Studies<br><br>**Note:** DSR appendices typically include different content than IB appendices |

---

## SECTION 10: SUMMARY TABLES FOR DSR

### Table 1: Comparative Safety Data

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **Comparative safety table** | Section 5.5.1.2 | 88-95 | For ARROW study, compare:<br>- Different dose cohorts from Phase I<br>- 400 mg QD Phase II population<br>**Note:** Direct comparator arm data not available for monotherapy studies |

### Table 2: Distribution by MedDRA PT

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **AE distribution tables** | Multiple tables | 89-92 | Extract from:<br>- Table 23: AEs occurring in ≥20% (any grade)<br>- Table 24: Treatment-related AEs ≥20%<br>- Table 25: Grade ≥3 AEs ≥10%<br>- Table 26: SAEs ≥2%<br>- Table 29: Summary of ADRs in ARROW Study (p. 105-107) |

### Table 3: Patient Characteristics Summary

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **Patient demographics** | Limited in IB | Various | **Very limited demographic data in IB**<br>- Some age ranges may be in Special Populations (Section 6.6)<br>- Full demographics tables in CSRs, not IB |

### Table 4: Laboratory Abnormalities

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **Lab abnormalities** | Section 5.5.1.2 | 88-95 | Table 30: Pralsetinib Treatment-Emergent Shifts of Key Laboratory Abnormalities (p. 107)<br>- Hematology<br>- Chemistry<br>- Shifts from baseline |

### Table 5: Outcome by Action Taken

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **Action taken analysis** | Section 5.5.1.2.6-7 | 92-93 | - Section 5.5.1.2.6: AEs leading to withdrawal<br>- Section 5.5.1.2.7: AEs leading to dose modification<br>**Note:** Detailed outcome by action matrices typically in CSRs |

---

## SECTION 11: SPECIAL POPULATIONS & DRUG INTERACTIONS

### Special Populations

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **Pregnancy** | Section 6.6.1 | 112 | Pregnancy warnings and precautions |
| **Nursing Mothers** | Section 6.6.2 | 112 | Lactation information |
| **Children** | Section 6.6.3 | 113 | Pediatric population (approved for ≥12 years) |
| **Geriatric Patients** | Section 6.6.4 | 113 | Elderly population considerations |
| **Hepatic Impairment** | Section 6.6.5 | 113 | Also Section 5.2.5 (p. 76-80): Study GP43163 - Hepatic Impairment PK study |
| **Renal Impairment** | Not extensively covered | N/A | Limited renal impairment data in IB |

### Drug Interactions

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **Impact of other drugs on pralsetinib** | Section 6.7.1 | 113-114 | - CYP3A inhibitors (strong/moderate)<br>- CYP3A inducers<br>Also: Section 5.2.4 (p. 68-76) for DDI study results |
| **Impact of pralsetinib on other drugs** | Section 6.7.2 | 114 | - P-gp substrates<br>- CYP2C8 substrates<br>- CYP3A substrates<br>Also: Section 4.2.7 (p. 33-34) for nonclinical DDI data |

---

## SECTION 12: PHARMACOKINETICS DATA

### Clinical PK Parameters

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **PK parameters - NSCLC** | Section 5.2.1.1 | 47-51 | - Table 7: PK Parameters (Single Dose & Steady State, QD)<br>- Table 8: PK Parameters (Twice Daily Doses)<br>- Figure 2: Concentration-time profiles |
| **PK parameters - Thyroid** | Section 5.2.1.2 | 52-57 | - Table 9: PK Parameters for All Thyroid Patients (QD)<br>- Table 10: PK Parameters (Twice Daily)<br>- Figure 3: Concentration-time profiles |
| **PK parameters - Tumor Agnostic** | Section 5.2.1.3 | 58-60 | Table 11: PK Parameters for Tumor-Agnostic Patients |
| **PK parameters - Other Indications** | Section 5.2.1.4 | 60-64 | - Table 12: Group 6 PK Parameters<br>- Table 13: Group 7 PK Parameters |

### ADME Studies

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **Mass Balance** | Section 5.2.2.1 | 64-68 | **Study BP42860**<br>- Table 14: Percentage of Metabolites<br>- Figure 4: Cumulative radioactivity excretion<br>- Figure 5: Biotransformation pathways |
| **Bioequivalence** | Section 5.2.2.2 | 68 | Study BP42859 |
| **Food Effect** | Section 5.2.4.1 | 68-70 | **Study BP42858**<br>- Table 15: PK parameters under fasted vs. fed<br>- Figure 6: Concentration-time profiles |
| **DDI - Itraconazole/Rifampin** | Section 5.2.4.2 | 70-72 | Study BP42861 |
| **DDI - Esomeprazole** | Section 5.2.4.3 | 72-73 | **Study BP42862**<br>- Table 16: PK with/without esomeprazole |
| **DDI - Cyclosporine** | Section 5.2.4.4 | 73-76 | **Study GP43162**<br>- Table 17: PK parameters |

---

## SECTION 13: IDENTIFIED SAFETY RISKS - DETAILED MAPPING

### Interstitial Lung Disease/Pneumonitis

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **Description** | Section 6.3 | 100 | "Cases of severe, life-threatening, and fatal pneumonitis/interstitial lung disease (ILD) have been reported" |
| **Clinical characterization** | Section 6.4, Table 28 | 101-107 | Detailed risk characterization in identified risks table |
| **Management** | Section 6.3 | 100 | "Patients should be monitored for acute or worsening of pulmonary symptoms" |

### Hepatotoxicity

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **Description** | Section 6.4, Table 28 | 102 | ALT/AST elevations |
| **Clinical data** | Table 30 | 107 | Laboratory abnormalities - hepatic enzymes |
| **Management** | Section 6.3-6.4 | 100-107 | Monitoring and dose modification recommendations |

### Hemorrhagic Events

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **Description** | Section 6.4, Table 28 | 103 | Bleeding events of various severities |
| **Clinical data** | Section 5.5.1.2.8 | 93 | Selected Adverse Events section |

### Hypertension

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **Description** | Section 6.4, Table 28 | 103 | Blood pressure elevations |
| **DLT data** | Table 22 | 88 | Hypertension was a DLT in dose escalation |
| **Clinical data** | Section 5.5.1.2.8 | 93 | Selected Adverse Events |

### Tumor Lysis Syndrome

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **Description** | Section 6.4, Table 28 | 104 | TLS risk characterization |
| **DLT data** | Table 22 | 88 | TLS was a DLT at 300 mg QD |

### Severe Infections (NEW IN VERSION 10)

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **Description** | Section 6.3 | 100 | **NEWLY ADDED** warnings and precautions for severe infections |
| **Clinical characterization** | Section 6.4, Table 28 | 104 | **NEWLY ADDED** to identified risks table |
| **Version history** | Page 2 | 2 | Listed in "Summary of Significant Changes":<br>"Section 6.3: Updated warnings and precautions for severe infections"<br>"Section 6.4: Added severe infections details to identified risks table" |

### Wound Healing Complications

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **Description** | Section 6.4, Table 28 | 104 | Impaired wound healing risk |

### Embryo-Fetal Toxicity

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **Description** | Section 6.4, Table 28 | 104 | Reproductive toxicity |
| **Nonclinical data** | Section 4.3.6 | 38-39 | Reproductive and Developmental Toxicity studies |
| **Warnings** | Section 6.6.1 | 112 | Pregnancy warnings |

---

## SECTION 14: REFERENCE SAFETY INFORMATION (RSI)

### Expected Serious Adverse Reactions (SARs)

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **Adult population SARs** | Section 6.4.1.1 | 108-110 | **Table 31: Serious Adverse Reactions to Pralsetinib in Adult Patients Considered Expected for Safety Reporting Purposes**<br>Complete list of expected SARs by SOC and PT |
| **Pediatric population SARs** | Section 6.4.1.2 | 110 | **Table 32: Serious Adverse Reactions to Pralsetinib Considered Expected for Safety Reporting Purposes in Pediatrics**<br>Note: Same as adult population for patients ≥12 years |

---

## SECTION 15: POTENTIAL RISKS (UNDER EVALUATION)

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **Potential risks list** | Section 6.5 | 110-112 | **Table 33: Summary of Potential Risks**<br>Risks under evaluation but not yet confirmed |

---

## SECTION 16: CONTRAINDICATIONS & OVERDOSE

| Template Field | IB Source Section | IB Page(s) | Mapping Details |
|---|---|---|---|
| **Contraindications** | Section 6.2 | 99 | "Pralsetinib is contraindicated in patients with a known hypersensitivity to pralsetinib or any of the excipients" |
| **Overdose management** | Section 6.8 | 114 | Limited information on overdose management |

---

## SECTION 17: LIMITATIONS & GAPS IN IB DATA

### Information NOT Available in Investigator Brochure:

1. **Individual Patient Case Narratives**
   - Complete demographic details for specific cases
   - Detailed medical histories
   - Complete clinical courses with daily updates
   - Individual laboratory values and trends
   - Individual causality assessments
   - **Source:** Clinical Study Reports (CSRs), Safety Database

2. **Detailed Safety Database Analysis**
   - Case analysis strategies
   - Search term algorithms
   - Detailed case-by-case tabulations
   - Geographic distribution details
   - Reporter type distributions
   - **Source:** Safety Database queries, DSR-specific analyses

3. **Epidemiological Background**
   - Population-level disease epidemiology
   - General infection epidemiology in cancer patients
   - Comparative data with other oncology drugs
   - **Source:** Published literature, external databases

4. **Comparative Effectiveness Data**
   - Head-to-head comparisons with other RET inhibitors
   - Standard of care comparisons
   - **Source:** External literature, indirect comparisons

5. **Complete Demographic Tables**
   - Full demographic breakdowns by study
   - Exposure durations
   - Baseline characteristics tables
   - **Source:** CSRs

6. **Detailed Dose Modification Tables**
   - Complete dose modification algorithms
   - Detailed management by grade
   - **Source:** Study protocols, prescribing information

7. **Complete MedDRA Coding**
   - Full hierarchies (HLT, HLGT)
   - SMQs (Standardized MedDRA Queries)
   - **Source:** Safety database coding, MedDRA browser

8. **Statistical Analysis Plans**
   - Detailed statistical methodologies
   - Adjusted analyses
   - Subgroup analyses plans
   - **Source:** Statistical Analysis Plans (SAPs)

---

## SECTION 18: BEST PRACTICES FOR USING THIS MAPPING

### Priority 1: Direct Extraction (High Confidence)
These can be copied directly or with minimal adaptation:
- Drug names, RO numbers, trade names
- Approved indications (Section 6.1)
- Contraindications (Section 6.2)
- Physical/chemical properties (Section 3)
- Study designs and population descriptions
- Summary safety tables (Tables 23-30)
- Reference Safety Information (Tables 31-32)

### Priority 2: Synthesis Required (Moderate Effort)
These require combining multiple IB sections:
- Executive summary
- Drug background
- Therapeutic context
- Toxicology summaries
- Pharmacology background
- Risk characterization

### Priority 3: External Sources Needed (Cannot Populate from IB)
These require additional documentation:
- Individual case narratives
- Detailed case analysis strategies
- Complete demographic tables
- Epidemiological background
- Discussion and interpretation
- Comparative data
- Limitations sections

### Quality Control Checkpoints:

1. **Always cite IB version and date** when using IB data
2. **Cross-reference page numbers** for traceability
3. **Note data cutoff dates** for clinical data
4. **Identify gaps** where IB data is insufficient
5. **Supplement with CSRs** for detailed case information
6. **Use safety database** for case-level details
7. **Consult literature** for epidemiological context

### Automation Considerations:

**Good candidates for AI-assisted extraction:**
- Summary tables (Tables 23-30)
- Study design descriptions
- Mechanism of action text
- Identified risks descriptions
- Reference lists

**Poor candidates for AI-assisted extraction:**
- Individual case narratives (not in IB)
- Detailed causality assessments (not in IB)
- Epidemiological background (not in IB)
- Discussion synthesis (requires expert interpretation)
- Novel safety signal analysis (requires expert judgment)

---

## SECTION 19: VERSION CONTROL & UPDATES

**IB Version:** 10 (April 2025)
**Previous Version:** 9 (April 2024)

**Key Changes in Version 10 Relevant to DSR:**
1. ✅ **Severe infections** added to identified risks (Section 6.3-6.4)
2. Updated clinical data for Studies BO42863 and ML42439
3. Updated pharmacokinetic data
4. Updated marketing experience numbers

**Important:** When IB is updated to Version 11, this mapping should be reviewed for:
- New safety signals
- Updated patient exposure numbers
- New study data
- Changes to identified risks
- Updates to Reference Safety Information

---

## DOCUMENT METADATA

**Mapping Created:** [Current Date]
**Mapped By:** [Your Name/Team]
**IB Source Document:** Investigator's Brochure: RO7499790 (pralsetinib/GAVRETO), Version 10, April 2025
**DSR Template:** Drug Safety Report Template (Version as uploaded)
**Purpose:** Manual mapping for subsequent automation or manual population
**Review Status:** Initial comprehensive mapping - requires validation with actual use case

---

## APPENDIX: QUICK REFERENCE PAGE NUMBER INDEX

### Most Frequently Used IB Sections for DSR:

| Content Type | IB Section | Pages |
|---|---|---|
| Drug names & basics | Title page, Section 1.1 | 1, 15 |
| Approved indications | Section 6.1 | 99 |
| Identified risks | Section 6.4, Table 28 | 101-107 |
| Clinical safety summary | Section 1.4.3 | 22 |
| ARROW study safety | Section 5.5.1 | 87-95 |
| MyTACTIC safety | Section 5.5.4 | 96-99 |
| AE tables (any grade) | Table 23 | 89 |
| Treatment-related AEs | Table 24 | 90 |
| Grade ≥3 AEs | Table 25 | 91 |
| Serious AEs | Table 26 | 91-92 |
| Deaths | Section 5.5.1.2.4 | 91 |
| ADR summary | Table 29 | 105-107 |
| Lab abnormalities | Table 30 | 107 |
| Expected SARs | Tables 31-32 | 108-110 |
| Toxicology - Hematologic | Section 4.3.3.1 | 36 |
| Warnings & Precautions | Section 6.3 | 100 |
| Marketing experience | Section 5.6 | 99 |
| References | Section 7 | 115-119 |

---

**END OF COMPREHENSIVE MAPPING DOCUMENT**
